

## Original Article

## Association of Serum Homocysteine with Gestational Diabetes Mellitus (GDM): A Case-Control Study

M Nessa<sup>1</sup>, TR Das<sup>2</sup>, E Jahan<sup>3</sup>, MMUR khan<sup>4</sup>

### Abstract:

Gestational diabetes mellitus (GDM) is associated with an increased risk of maternal and fetal mortality and morbidity. There is an increasing trend in the prevalence of GDM in Bangladesh. The role of homocysteine (Hcy) as an independent risk factor of GDM has not been extensively studied. The aim of this study was to evaluate the association of serum homocysteine levels in gestational diabetes mellitus. It was a case-control study among pregnant women attending the inpatient and outpatient departments of Obstetrics and Gynecology, BSMMU, Shahbag Dhaka, from April 2020 to March 2021. A total of 80 singleton pregnant women between 18-35 years of age were included in this study in their 24-40 weeks of gestation. Among them, 40 diagnosed women with GDM were considered as the cases and the rest of the 40 matched healthy pregnant women were selected as controls matching for age and gestational age. The overall average Hcy levels in the cases and controls were  $5.48 \pm 1.3 \mu\text{mol/L}$  and  $4.06 \pm 0.98 \mu\text{mol/L}$ , respectively. Both in the late second trimester and the third-trimester serum Hcy levels were significantly higher in the GDM cases than non-GDM healthy pregnant women ( $p < 0.05$ ). Considering Hcy level of  $6.38 \mu\text{mol/L}$  as the cut-off value, GDM was 4.75 times more likely in pregnant women with elevated serum Hcy level ( $\geq 6.38$ ) than those with  $< 6.38 \mu\text{mol/L}$  ( $OR = 4.75$ ;  $95\% \text{ CI} = 0.941-23.985$ ). There was a significant positive correlation of serum Hcy level with both fasting blood sugar level ( $r = +0.600$ ,  $p < 0.001$ ) and 2 hrs after 75g glucose level ( $r = +0.438$ ,  $p < 0.001$ ). Elevated level of serum homocysteine was found associated with GDM.

**Key words:** GDM, Homocysteine (Hcy) level.

### Introduction:

Gestational diabetes mellitus (GDM) is exhibited as carbohydrate intolerance resulting in hyperglycemia of variable severity with onset or first recognition during pregnancy<sup>1</sup>. It is the foremost common metabolic disorder throughout gestation that may cause several maternal and fetal complications during pregnancy and

postnatal period. Women with GDM generally have few symptoms and it is most commonly recognized by screening during pregnancy<sup>2</sup>. It results in an increased maternal risk of preeclampsia, preterm labor, polyhydramnios, vaginal tearing, cesarean section and recurrent GDM and type-2 diabetes in later life. The

1. Dr. Meherun Nessa, MBBS, MS (Obstetrics and Gynaecology), Assistant Gynaecologist, Nova Fertility Bangladesh Private limited, Dhaka.
2. Prof. Dr. Tripti Rani Das, MBBS, FCPS (Obstetrics and Gynaecology), MS (Obstetrics and Gynaecology), Professor, Department of Obstetrics & Gynecology, Bangabandhu Sheikh Mujib Medical University, Shahbag, Dhaka.

3. Dr. Esrat Jahan, MS (Obstetrics and Gynaecology), Lecturer, Department of Community Medicine, Bangabandhu Sheikh Mujib Medical College, Faridpur.
4. Dr. Md. Munim-Ur-Rahman Khan, MPH (Epidemiology), Assistant Professor (CC), Department of Community Medicine, Bangabandhu Sheikh Mujib Medical college, Faridpur

### Address of correspondence:

Dr. Md. Munim-Ur-Rahman Khan, MPH (Epidemiology), Assistant Professor (CC), Department of Community Medicine, Bangabandhu Sheikh Mujib Medical college, Faridpur. Phone: +8801712166948, E-mail: [munim2812@gmail.com](mailto:munim2812@gmail.com)

major fetal and neonatal complications include perinatal mortality, macrosomia, obstetric trauma, hypoglycemia, hyperbilirubinemia, hypocalcemia and increased risk of obesity<sup>3</sup>.

Irrespective of variations in the population characteristics, screening methods and diagnostic criteria, an estimated 1-28% of pregnancies worldwide are impacted by the complications of GDM<sup>4</sup>. The prevalence of GDM in the U.S. was 7.6%,<sup>5</sup> while it reportedly affects one in every 23 pregnancies in the UK<sup>6</sup>. On the other hand, Bangladesh is the least developed country in Southeast Asia where maternal and child health is still underprivileged at some places with less access to healthcare services<sup>7</sup>. Here, the prevalence of GDM has been progressively increasing from 7.5% in 2012 to 18.1% in 2018<sup>8</sup>.

In a normal pregnancy, there is an increase in insulin resistance (IR) which emerges in the second trimester and progresses over the late third trimester, is caused by increasing maternal weight and circulating hormonal factors produced by the mother and placenta, including human placental lactogen, progesterone, growth hormone, cortisol, and prolactin. To compensate for the peripheral IR during pregnancy, insulin secretion increases from a woman's pancreas. However, in women who develop GDM, there is diminished pancreatic  $\beta$ -cell reserve and the production of insulin fails to keep up with the increased insulin demand resulting in hyperglycemia. In addition, increased maternal adipose deposition, decreased exercise and increased calorie intake contribute to this state of relative glucose intolerance<sup>9,10</sup>.

An increased level of oxidative stress is an important aspect of GDM that is involved in vascular damage and metabolic alterations<sup>11</sup>. Homocysteine (Hcy) is a sulfur-containing amino acid formed during the metabolism of methionine. Elevated plasma Hcy concentration may induce excessive production of reactive oxygen species and impair the glutathione-related antioxidant defense system, leading to greater oxidative stress and lower antioxidant enzymatic activities<sup>12</sup>. Therefore, elevated maternal serum Hcy level could promote IR by inducing endoplasmic reticulum stress or up-regulating resistin production in adipose tissue,<sup>13</sup> which exaggerates  $\beta$ -cells function and results in GDM. Furthermore, during gestational diabetes, Hcy levels might increase, while serum Vit B12 and folic acid levels are known to decrease during GDM<sup>14,15</sup>.

A large number of studies have focused on the relationship between Hcy and diabetes; however, the investigations between homocysteine and GDM were much fewer and their results were inconsistent. Likewise, in Bangladesh, there is a very limited number

of studies on homocysteine levels in women with GDM. The present study aimed to evaluate the association of serum Hcy level with GDM. From the knowledge of the study, physicians might be able to assess the risk of developing GDM with the initiation of early effective management for prevention of the morbid effects and life-threatening consequences of GDM.

### Materials and methods:

This case-control study was carried out on pregnant women attending the outpatient and inpatient departments of the Department of Obstetrics and Gynecology, Bangabandhu Sheikh Mujib Medical University (BSMMU), Shahbag, Dhaka from April 2020 to March 2021 for prenatal care. A total of 40 cases and 40 controls who agreed to participate in the study were enrolled for this study upon fulfilling the selection criteria. Cases consisted of patients with GDM and controls comprised of healthy women without GDM matched for age between 18-35 years and gestational age 24-40 weeks. Data were collected from the patients on variables of interest using the semi-structured questionnaire designed for the interview, observation, clinical examination, hematological investigations and from hospital records of the patients. All the participants underwent standardized anthropometric measurements. With proper aseptic precautions, 3 ml of blood was collected from the ante-cubital vein using a sterile needle and syringe to estimate serum Hcy level. The blood sample was transferred into a clean, dry test tube and then taken for analysis to the laboratory of Department of Biochemistry and Molecular Biology, BSMMU where the total serum Hcy levels were determined by using an Alinity i Homocysteine Reagent Kit 09P28 in an automated analyzer (Atellica, Siemens, Germany). For this study purpose Hcy level 6.38  $\mu\text{mol/L}$  was taken as cut off value,<sup>16</sup> above which level it was considered a risk for developing GDM. All of the participants' oral glucose tolerance test (OGTT) reports were collected from their recent hospital records. GDM was diagnosed at the late second and third trimester of pregnancy if one or more of the following diagnostic criteria (WHO, 2013) were met - fasting plasma glucose: 5.1-6.9 mmol/l (92-125 mg/dl) and/or 2-hours plasma glucose following a 75 g oral glucose load: 8.5-11.0 mmol/l (153-199 mg/dl)<sup>1</sup>. Collected data were analyzed and compared using SPSS software v 26.0. A p-value less than 0.05 was considered statistically significant. The study was approved by the Institutional Review Board, BSMMU.

**Results:**

A total of 40 cases and 40 controls were enrolled in this study. The mean age was 28.7±3.45 years in the case group and 28.5±3.60 years in the control group. The majority of the patients were educated to the primary level, 42.5% in cases and 47.5% in the controls. Above four-fifth (82.5%) of the patients were homemakers among the cases compared to three-fourths (75%) of the control groups. Maximum participants (cases: 87.5%, and controls: 80.0%) had monthly family income between 15,000 to 30,000 BDT. These differences were not statistically significant between the case and control groups (Table I).

**Table I:** Distribution of patients according to socio-demographic characteristics of the study population.

Socio-demographic characteristics	Case (n = 40)		Control (n = 40)		p-value
	N	%	N	%	
<b>Age (in years)</b>					
Mean ± SD	28.7 ± 3.45		28.5 ± 3.60		<sup>a</sup> 0.825 <sup>ns</sup>
Range (min – max)	(18 – 35)		(18 – 35)		
<b>Education</b>					
Illiterate	10	25.0	7	17.5	<sup>b</sup> 0.713 <sup>ns</sup>
Primary	17	42.5	19	47.5	
Secondary & above	13	32.5	14	35.0	
<b>Occupation</b>					
Homemaker	33	82.5	30	75.0	<sup>b</sup> 0.433 <sup>ns</sup>
Student	4	10.0	8	20.0	
Service holder	3	7.5	2	5.0	
<b>Monthly household income (in taka)</b>					
15,000 to 30,000 BDT	35	87.5	32	80.0	<sup>b</sup> 0.363 <sup>ns</sup>
> 30,000 BDT	5	12.5	8	20.0	

ns = not significant

<sup>a</sup>p value reached from unpaired t-test

<sup>b</sup>p value reached from chi-square test

Majority of the respondents were on their third trimester of pregnancy in both groups (cases: 72.5% and controls: 75.0%). Total 80.0% of patients in the control group were multigravida, compared to 70% in the case group. In this study, gestational age in the cases was 31.4±4.20 weeks and in the control group 32.4±4.80 weeks. Majority of the of patients' BMI belonged to 25-29.9 kg/m<sup>2</sup> (overweight) in both groups, which were 82.5% in case and 75.0% in control groups. These differences were not statistically significant (p >0.05) between the two groups (Table II).

**Table II:** Distribution of patients according to obstetric and anthropometric parameters of the study population

Obstetrical and anthropometric parameters	Case (n = 40)		Control (n = 40)		p value
	N	%	N	%	
<b>Gravida</b>					
Primi	12	30.0	8	20.0	<sup>a</sup> 0.302 <sup>ns</sup>
Multi	28	70.0	32	80.0	
<b>Trimester of pregnancy</b>					
Second trimester	11	27.5	10	25.0	<sup>a</sup> 0.799 <sup>ns</sup>
Third trimester	29	72.5	30	75.0	
<b>Gestational age (in weeks)</b>					
Mean ± SD	31.4 ± 4.20		32.4 ± 4.80		<sup>b</sup> 0.301 <sup>ns</sup>
Range (min – max)	(24 – 38)		(24 – 39)		
<b>Body mass index (kg/m<sup>2</sup>)</b>					
Normal (18.5 – 24.9)	5	12.5	10	25.0	
Overweight (25.0 – 29.9)	33	82.5	30	75.0	
Obese (≥ 30)	2	5.0	0	0.0	
Mean ± SD	27.6 ± 1.76		27.0 ± 1.98		<sup>b</sup> 0.144 <sup>ns</sup>
Range (min – max)	(23.9 – 32.5)		(22.7 – 29.8)		

ns = not significant

<sup>a</sup>p value reached from chi-square test

<sup>b</sup>p value reached from unpaired t-test

There was no significant difference in distribution of the study subjects according to their previous history of obstetrical complications (p>0.05), though in cases preterm delivery and congenital birth defects were observed more, 28.6% and 3.6% respectively, than the controls (Table III).


**Table III:** Distribution of study population according previous obstetrical complications (in multigravid respondents)

Previous obstetrical complications	Case (n = 28)		Control (n = 32)		p value
	N	%	N	%	
<b>History of preterm delivery</b>					
Yes	8	28.6	3	9.4	<sup>a</sup> 0.094 <sup>ns</sup>
No	20	71.4	29	90.6	
<b>History of congenital defect of baby</b>					
Yes	1	3.6	0	0.0	<sup>a</sup> 0.467 <sup>ns</sup>
No	27	96.4	32	100.0	

ns = not significant

<sup>a</sup>p value reached from chi-square test

Mean Hcy was found  $5.48 \pm 1.30 \mu\text{mol/L}$  in cases and  $4.06 \pm 0.98 \mu\text{mol/L}$  in control group. The difference between two groups was statistically significant ( $p < 0.001$ ) (Figure 1).



**Figure 1:** Distribution of maternal serum Hcy level in the study population (cases =  $5.48 \pm 1.30 \mu\text{mol/L}$  and controls =  $4.06 \pm 0.98 \mu\text{mol/L}$ ,  $p < 0.001$ )

There was a significant difference in regards to raised Hcy level in between case and control groups ( $p = 0.043$ ), and the respondents with Hcy level  $\geq 6.38 \mu\text{mol/L}$  had 4.75 times more chance to develop GDM compared to that of the respondent with homocysteine level  $< 6.38 \mu\text{mol/L}$  (OR=4.750; 95% CI = 0.941-23.985) (Table V).



**Table V:** Odds ratios (OR) and 95% confidence intervals (CI) for GDM according serum homocysteine level in pregnancy (n=80)

Serum Hcy (μmol/L)	Groups		p-value	OR (95% CI)
	Case n(%) (n=40)	Control n(%) (n=40)		
$\geq 6.38$	8 (80.0)	2 (20.0)	$0.043^*$	4.75 (.941-23.985)
$< 6.38$	32 (45.7)	38 (54.3)		

\*significant

<sup>a</sup>p value reached from chi-square test

Figure 2: observed a significant positive correlation of maternal serum Hcy level with both fasting blood sugar and 2 hours after 75g of glucose blood sugar ( $r = +0.600$ ,  $p < 0.001$  and  $r = 0.438$ ,  $p < 0.001$ , respectively).



**Figure 2:** Scatterplot diagram showing the correlation between maternal FBS and 2HA 75g glucose blood sugar with serum homocysteine level

### Discussion:

An elevated plasma Hcy level may increase the overall risk of GDM. This case-control study was carried out to evaluate the association of maternal serum Hcy level with GDM, and therefore measure serum Hcy level of normal healthy pregnant and women with GDM in their 24 to 40 weeks of gestation.

Based on the results of this study, the mean serum total Hcy concentration was significantly ( $p < 0.001$ ) higher among women with GDM ( $5.48 \pm 1.30 \mu\text{mol/L}$ ) than that of normal controls ( $4.06 \pm 0.98 \mu\text{mol/L}$ ) and both in the second and third trimester of pregnancy serum Hcy levels were found significantly higher than the normal healthy pregnant women. This finding is similar to that reported by Seghieri and associate, where serum Hcy was significantly higher in the group with GDM compared with nondiabetic women<sup>17</sup>.

In this study, the majority of the respondents were between 24-29 years of age groups, 42.5% in the cases and 47.5% in the controls. The majority of respondents (45.0%) were educated up to the primary level, while 21.2% were found illiterate. Above three-quarters of the patients were homemakers (78.8%), and the monthly family income was between 15000-30000 Taka (83.8%). No statistical significance was observed regarding the study population's socio-demographic characteristics. These findings were supported by Cheung and Byth, who enumerated that socially disadvantaged GDM women are less likely to seek perinatal care<sup>18</sup>.

In the present study majority of the respondents belonged to their third trimester of pregnancy, 72.5% and 75.0% in case and control groups, respectively,



while three-quarter of the study subjects (75.0%) were multigravida. Gestational age was taken as matching criteria, with the mean ( $\pm$ SD) duration of the respondents' gestational age was 31.4 $\pm$ 4.20 weeks among the cases and 32.4 $\pm$ 4.80 weeks in the control group. The overall average body mass index (BMI) in this study subjects were found almost similar 27.6 $\pm$ 1.76 kg/m<sup>2</sup> among the case group and 27.0 $\pm$ 1.98 kg/m<sup>2</sup> in the control group. According to Carpenter,<sup>19</sup> gravidas with GDM generally demonstrate higher degrees of post-pregnancy insulin resistance,  $\beta$ -cell dysfunction, higher BMI, central obesity, and exaggerated hyperlipidaemia, suggesting that GDM is a transient manifestation of long standing metabolic dysfunction.

In the current study, previous obstetrical complications and the number of babies with congenital defects were very low and did not show any statistical significance ( $p>0.05$ ), though history of preterm delivery was seen in 28.6% of the cases and history of congenital defect of baby in 3.6%. Among the study subjects, 27.5% of the cases and 12.5% of the controls had a positive family history of GDM ( $p=0.094$ ). According to Steegers-Theunissen and associates, there was a significant relation between tHcy concentration and stillbirth, neural tube defects, and clubfoot with plasma Hcy<sup>20</sup>.

The respondents with Hcy level  $\geq 6.38$   $\mu\text{mol/L}$  had 4.75 times more chance to develop GDM compared to that of the respondent with homocysteine level  $< 6.38$   $\mu\text{mol/L}$  (OR=4.750; 95% CI = 0.941-23.985). Moreover, the correlation between maternal serum Hcy level and fasting and 2 hours after 75g of glucose blood sugar showed significant positive correlations. This backs our hypothesis that elevated serum Hcy level is associated with GDM.

These findings co-relate with reports by Sharmila, who revealed there is significant association between homocysteine with GDM and hyperhomocysteinemia was found in 56.66% of patients with GDM<sup>21</sup>. Movahed and associates, in their study observed, in GDM, serum Hcy level was significantly higher ( $P<0.001$ ), and folic acid was significantly lower ( $P<0.001$ ) than normal pregnancy group<sup>22</sup>. They concluded that folic acid has a role in the regulation of serum Hcy level and blood sugar. Deng et al. also found women with GDM had a higher plasma Hcy level than normal glucose tolerant (NGT) women (6.61  $\pm$  1.32 vs. 6.17  $\pm$  1.29  $\mu\text{mol/L}$ ,  $P = 0.001$ ). The GDM risk was 1.79 (OR=1.79, 95% CI 1.18–2.72,  $P=0.006$ ) times higher in women whose plasma tHcy level was  $\geq 7.29$   $\mu\text{mol/L}$  compared to women with plasma tHcy level  $< 5.75$   $\mu\text{mol/L}$ <sup>23</sup>.

Though the current study was conducted in a selected tertiary level hospital with small sample size, therefore, all the findings of this study had given rise to concerns about higher level of serum homocysteine among the GDM patients.

### Conclusion:

In this study, findings conveyed that elevated maternal Hcy level was associated with GDM. And it is recommended that screening for hyperhomocysteinemia might be considered a part of the routine antenatal check-up. Further multi-centric study with a larger sample size could be done to determine the validity of the findings of the present study.

### References:

1. World Health Organization. Diagnostic criteria and classification of hyperglycaemia first detected in pregnancy. No. WHO/NMH/MND/13.2. World Health Organization. 2013.
2. Gong T, Wang J, Yang M, Shao Y, Liu J, Wu Q, et al. Serum homocysteine level and gestational diabetes mellitus: A meta-analysis. *Journal of diabetes investigation*. 2016 Jul;7(4):622-8.
3. Poulakos P, Mintziori G, Tsirou E, Taousani E, Savvaki D, Harizopoulou V, et al. Comments on gestational diabetes mellitus: from pathophysiology to clinical practice. *Hormones*. 2015 Jul;14(3):335-44.
4. Jiwani A, Marseille E, Lohse N, Damm P, Hod M, Kahn JG. Gestational diabetes mellitus: results from a survey of country prevalence and practices. *The Journal of Maternal-Fetal & Neonatal Medicine*. 2012 Jun 1;25(6):600-10.
5. Casagrande SS, Linder B, Cowie CC. Prevalence of gestational diabetes and subsequent type 2 diabetes among US women. *Diabetes research and clinical practice*. 2018 Jul 1;141:200-8.
6. Walsh S, Mahmoud M, Htun H, Hodgett S, Barton D. A comparison of follow-up rates of women with gestational diabetes before and after the updated National Institute for Health and Care Excellence guidance advocating routine follow-up, and the association with neighbourhood deprivation. *British Journal of Diabetes*. 2019 Jun 27;19(1):14-8.
7. Banik BK, Sumon MS. Barriers to access maternal health services among urban poor women in Bangladesh: A Case of Rajshahi City. *South East Asia Journal of Public Health*. 2018;8(1):22-31.

8. Kim Y, Lee JL, Jang IS, Park S. Knowledge and Health Beliefs of Gestational Diabetes Mellitus Associated with Breastfeeding Intention Among Pregnant Women in Bangladesh. *Asian Nursing Research*. 2020;14(3):144-9.
9. Alfadhli EM. Gestational diabetes mellitus. *Saudi medical journal*. 2015;36(4):399.
10. Panaitescu AM, Peltecu G. Gestational diabetes. Obstetrical perspective. *Acta Endocrinologica (Bucharest)*. 2016 Jul;12(3):331.
11. Zhu C, Yang H, Geng Q, Ma Q, Long Y, Zhou C, et al. Association of oxidative stress biomarkers with gestational diabetes mellitus in pregnant women: a case-control study. *PloS one*. 2015 Apr 27;10(4):e0126490.
12. Liu HH, Shih TS, Huang HR, Huang SC, Lee LH, Huang YC. Plasma homocysteine is associated with increased oxidative stress and antioxidant enzyme activity in welders. *The Scientific World Journal*. 2013 Jan 1;2013.
13. Li Y, Zhang H, Jiang C, Xu M, Pang Y, Feng J, et al. Hyperhomocysteinemia promotes insulin resistance by inducing endoplasmic reticulum stress in adipose tissue. *Journal of Biological Chemistry*. 2013 Apr 5;288(14):9583-92.
14. Idzior-Waluś B, Cyganek K, Sztéfko K, Seghieri G, Breschi MC, Waluś-Miarka M, et al. Total plasma homocysteine correlates in women with gestational diabetes. *Archives of gynecology and obstetrics*. 2008 Oct;278(4):309-13.
15. Begum SA, Khalil I, Mandal CK, Hasan MM, Kawsar MA. Folic acid deficiency related to hyperhomocysteinemia has less correlation with Gestational Diabetes Mellitus (GDM). *Update Dental College Journal*. 2016 Aug 13;6(1):1-7.
16. Cho NH, Lim S, Jang HC, Park HK, Metzger BE. Elevated homocysteine as a risk factor for the development of diabetes in women with a previous history of gestational diabetes mellitus: a 4-year prospective study. *Diabetes care*. 2005 Nov 1;28(11):2750-5.
17. Seghieri G, Breschi MC, Anichini R, De Bellis A, Alviggi L, Maida I, et al. Serum homocysteine levels are increased in women with gestational diabetes mellitus. *Metabolism*. 2003 Jun 1;52(6):720-3.
18. Cheung NW, Byth K. Population health significance of gestational diabetes. *Diabetes care*. 2003 Jul 1;26(7):2005-9.
19. Carpenter MW. Gestational diabetes, pregnancy hypertension, and late vascular disease. *Diabetes care*. 2007 Jul 1;30(Supplement 2):S246-50.
20. Steegers-Theunissen RP, Van Iersel CA, Peer PG, Nelen WL, Steegers EA. Hyperhomocysteinemia, pregnancy complications, and the timing of investigation. *Obstetrics & Gynecology*. 2004 Aug 1;104(2):336-43.
21. Sharmila R. A Comparative and Correlative Study of Serum Homocysteine Level in Gestational Diabetes Mellitus and Normal Pregnancy. *International journal of advances in medicine*. 2019;6(4).doi://doi.org/10.18203/2349-3933.ijam 20193296.
22. Movahed F, Hajiseyedjavadi E, Safari N, Yazdi Z. Comparison of serum homocystein and folic acid levels in gestational diabetes with normal pregnancy. *Avicenna Journal of Clinical Medicine*. 2015 Sep 15;22(2):93-8.
23. Deng M, Zhou J, Tang Z, Xiang J, Yi J, Peng Y, et al. The correlation between plasma total homocysteine level and gestational diabetes mellitus in a Chinese Han population. *Scientific Reports*. 2020 Oct 29;10(1):1-5.